PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-7.97
Both companies show losses. Martin Whitman would check if industry conditions create special situations.
601.61
P/S above 1.5x AGEN's 114.05. Michael Burry would check for mean reversion risks.
1.99
Positive equity while AGEN shows negative equity. John Neff would investigate balance sheet advantage.
-34.45
Both companies show negative FCF. Martin Whitman would check for industry-wide capital intensity issues.
-34.91
Both companies show negative operating cash flow. Martin Whitman would check for industry-wide operational issues.
1.99
Positive fair value while AGEN shows negative value. John Neff would investigate valuation advantage.
-3.14%
Both companies show losses. Martin Whitman would check for industry-wide issues.
-2.90%
Both companies show negative FCF. Martin Whitman would check for industry-wide capital intensity issues.